Scarica l'app Stockscreener
4.985
0.91%
0.045
Dopo l'orario di chiusura:
4.90
-0.085
-1.71%
Precedente Chiudi:
$4.94
Aprire:
$4.99
Volume 24 ore:
28,482
Relative Volume:
0.46
Capitalizzazione di mercato:
$16.04M
Reddito:
-
Utile/perdita netta:
$-37.68M
Rapporto P/E:
-0.4212
EPS:
-11.8364
Flusso di cassa netto:
$-30.65M
1 W Prestazione:
+4.95%
1M Prestazione:
+15.39%
6M Prestazione:
-41.42%
1 anno Prestazione:
-29.39%
Intervallo 1D:
$4.90
$5.2151
Intervallo di 1 settimana:
$4.63
$5.36
Portata 52W:
$3.29
$20.00
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Compare PASG vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PASG
Passage Bio Inc
|
4.985 | 15.90M | 0 | -37.68M | -30.65M | -11.84 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2026-04-21 | Downgrade | TD Cowen | Buy → Hold |
| 2026-04-21 | Downgrade | Wedbush | Outperform → Neutral |
| 2026-03-31 | Iniziato | Oppenheimer | Outperform |
| 2026-02-10 | Ripresa | Chardan Capital Markets | Buy |
| 2024-11-29 | Ripresa | Wedbush | Outperform |
| 2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
| 2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-01-19 | Downgrade | Goldman | Buy → Neutral |
| 2021-07-01 | Iniziato | Raymond James | Outperform |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-02-04 | Iniziato | Guggenheim | Buy |
| 2021-01-25 | Iniziato | Wedbush | Outperform |
| 2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2020-12-11 | Iniziato | Citigroup | Neutral |
| 2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-25 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
| 2020-03-24 | Iniziato | Cowen | Outperform |
| 2020-03-24 | Iniziato | Goldman | Buy |
| 2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today - Stocktwits
Layoff Tracker: Merck adds 53 jobs to New Jersey chopping block - BioSpace
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff? - Stocktwits
Passage Bio stock holds steady as investors weigh gene therapy pipeline and recent losses - ad-hoc-news.de
Passage Bio Amends Remix Merger, Private Financing Terms - TipRanks
[425] Passage BIO, Inc. Business Combination Communication | PASG SEC FilingForm 425 - Stock Titan
Passage Bio Revises Remix Merger to Two-Step Structure, Adds $70 Million Pre-Funded PIPE - TradingView
Remix deal would leave Passage Bio (NASDAQ: PASG) investors a small slice of the combined company - Stock Titan
Fierce Biotech Layoff Tracker 2026: Novartis nixes Swiss site; TScan telegraphs 75% headcount drop - Fierce Biotech
Passage Bio stock reacts to reverse split as investors watch next steps - ad-hoc-news.de
Passage (PASG) Earnings Update: EPS Exceeds Its Estimate in the Latest Reading; Trading Move: Shares Fall 0.22% in the Current UpdateTech Earnings Analysis - vinanet.vn
GM1 Gangliosidosis Market Research Explores Growth Within A $0.95 Billion Opportunity - openPR.com
Vestal Point Capital (PASG) filing shows no current Passage Bio share ownership - Stock Titan
Passage Bio | SCHEDULE 13G/A: Others - Moomoo
PASG Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2% Share GainSpecial Dividend Alert - vinanet.vn
Passage Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Passage Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Passage Bio Q2 Results: EPS beats estimates, losses narrow YoY - scanx.trade
Passage Bio Q2 net loss narrows 16.67% to $7.82 million - Bitget
Passage BIO, Inc. 2026: Revenue ($7.82M), Net income ($7.82M), EPS ($2.44) — 10-Q Summary - TradingView
PASG: Pending merger with Remix is vital as cash dwindles and operations wind down - TradingView
Passage Bio (PASG) outlines Q2 2026 loss, cash strain and Remix merger terms - Stock Titan
Passage Bio Inc expected to post a loss of $2.65 a shareEarnings Preview - TradingView
Passage Bio Inc (PASG) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CYBR.O Forecast — Price Prediction for 2026. Should I Buy CYBR.O? - Intellectia AI
Emerging Sub-Segments Transforming the Lysosomal Enzyme Market Landscape - openPR.com
REPX Q1 2026 Earnings: Deep EPS Miss Delivers -369.75% Surprise as Shares Gain 2.24%Revenue Breakdown Analysis - vinanet.vn
PASG Q2'26 Earnings: EPS estimate is (2.65) USD - TradingView
Passage Bio Inc. (PASG) Slips 3% as Shares Approach Key Support LevelHigh Volume Stocks - dars.gov.et
Passage Bio Inc (PASG) Cash Flow - TradingKey
Passage Bio Inc (PASG) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Passage Bio Inc (PASG) Institutional Confidence - TradingKey
Passage Bio Inc (PASG) Income Statement - tradingkey.com
Passage Bio Inc (PASG) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Passage Bio Inc (PASG) Valuation: PE, PB & Fair Value Analysis - TradingKey
Passage Bio Inc (PASG) Balance Sheet - TradingKey
PASG|Passage Bio Inc|Price:4.570|Chg%:-0.370 - TradingKey
PASG|Passage Bio Inc|Price:4.940|Chg%:+0.040 - TradingKey
Passage Bio Inc (PASG) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Passage Bio Inc (PASG) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Passage Bio, Inc. Revenue Breakdown – NASDAQ:PASG - TradingView
Passage Bio (PASG) Q1 2026 Earnings: Narrowed Loss Exceeds Expectations Amid Continued Pipeline ProgressProfit Recovery Report - dars.gov.et
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger—CRNX, SLP, NCSM, and PASG - Morningstar
$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--CRNX, SLP, NCSM, and PASG - Finansavisen
PASG Q2'26 Earnings: revenue estimate is 0 USD - TradingView
PASG Q1 2026 Earnings: Narrower-Than-Expected Loss Reflects Cost Discipline in Pre-Revenue PhaseFinal Results - vinanet.vn
Passage Bio (PASG) to merge with Remix in $100M-backed oncology deal - Stock Titan
Form 4 Passage Bio Inc For: 22 July By Investing.com - Investing.com Nigeria
Passage Bio | 425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactionsmoomoo - Moomoo
Passage Bio (NASDAQ: PASG) to merge with Remix Therapeutics in $346M stock deal - Stock Titan
Passage Bio Inc. (PASG) Q1 2026 Earnings: Narrower-Than-Expected Loss as Cost Controls SurpriseEarnings Cycle Outlook - dars.gov.et
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):